The Motley Fool reports that biotech stocks surged in 2025, driven by FDA approvals and a doubling of longevity investment to $8.49 billion.

This clinical-stage biotech develops bladder-sparing therapies for high-risk cancer patients, targeting unmet needs in oncology treatment.

This biotech firm develops targeted oncology therapies and leverages proprietary technology to address tumor resistance ...

This clinical-stage biotech develops precision therapies for genetically defined diseases, targeting rare cancers and ...

This clinical-stage biotech focuses on targeted cancer therapies and strategic partnerships in oncology and rare disease treatment.

Biotech picks highlight cystic fibrosis drug trials, rare-disease therapies and upcoming regulatory catalysts as clinical data and approvals approach.

Everyone should save money for retirement, since programs such as Social Security aren't meant to replace workers' entire ...

Even on a budget, you can get quality stocks.

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

After several years of IPO drought in the biotech industry, the public market is picking up again. Will the trend keep going in 2026?

Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay ...